PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:23 AM ET

Sponsor Check › Person

BB
No photo found yet (own website and image search run after this page is viewed)

Bruce Booth

Named as an officer, director or promoter on SEC Form D filings · CO, MA · Jul 31, 2009 → Sep 4, 2025

21deals (issuers)
$3.35Breported sold
747investors
47Form D filings
2009–2025years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:19 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Bruce Booth is listed as an executive officer and director on 47 SEC Form D filings by 21 issuers between May 2009 and Sep 2025. Largest by amount reported sold: Atlas Venture Fund XIV, L.P. (Cambridge, MA — pooled investment fund — 2024; $450M reported sold to 84 investors), Atlas Venture Fund XIII, L.P. (Cambridge, MA — pooled investment fund — 2022; $450M reported sold to 87 investors), Atlas Venture Opportunity Fund Ill, L.P. (Cambridge, MA — pooled investment fund — 2025; $400M reported sold to 84 investors), Atlas Venture Fund XII, L.P. (Cambridge, MA — pooled investment fund — 2020; $400M reported sold to 85 investors), Atlas Venture Fund XI, L.P. (Cambridge, MA — pooled investment fund — 2017; $350M reported sold to 70 investors) and 16 more (all listed below).

What this means That is a lot of deals — 21 separate companies raised money with this person listed as executive officer and director, over about 16 years. Across those companies the filings report $3.35B sold in total.

Listed alongside Thomas Hughes (14 shared filings), William Marshall (11 shared filings), Jason Rhodes (9 shared filings), Kyle Lefkoff (9 shared filings), David Grayzel (8 shared filings) and 99 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Bruce. Each name links to their own page.

The issuers belong to 3 sponsor groups: Atlas Venture (11 issuers, $2.66B reported sold, 2011–2026), Miragen Therapeutics (2 issuers, $131.7M reported sold, 2009–2020) and Tectonic Therapeutic (2 issuers, $265.1M reported sold, 2016–2025).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 1 bankruptcy case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 47 public filings for Bruce Booth and found 21 differences, 3 worth asking the sponsor about: 100% of the money raised went to insiders; Bruce Booth appears on 4 deals that stopped filing before reaching their target; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Bruce Booth has not run yet — it is #31,486 of 52,986 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:19 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Bruce Booth..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

Bruce A Booth and Miriam M Booth closed
United States Bankruptcy Court, S.D. Ohio · No. 3:14-bk-30482 · Filed Feb 24, 2014 · Closed Jun 18, 2014
Role of Bruce A Booth and Miriam M Booth: Debtor · Outcome: Case closed 2014-06-18 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 5 federal dockets); 2 people with this name in Form D filings; court in OH (not a filing state)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:19 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

21 differences found between the filings for Bruce Booth — 3 worth asking about (compared 47 filings on Oct 24, 2026)

Note · Jun 26, 2014 – Jul 11, 2014

Bankruptcy case: Helicos Biosciences Corporation v. Atlas Venture Fund VI, L.P. — filed Jun 26, 2014

United States Bankruptcy Court, D. Massachusetts docket "Helicos Biosciences Corporation v. Atlas Venture Fund VI, L.P." filed Jun 26, 2014, closed Jul 11, 2014. Atlas Venture Associates X, L.P. (listed on the same filings) is listed as Party ("Helicos Biosciences Corporation v. Atlas Venture Fund VI, L.P."). Our match estimate: 60%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, D. Massachusetts ↗Atlas Venture Associates X, L.P. — PartnerFacts page ↗
Sources
Note · Aug 12, 1994 – Dec 12, 1995

Bankruptcy case: Geoffrey S. Mackay and Christine P. Mackay — filed Aug 12, 1994

United States Bankruptcy Court, D. Massachusetts docket "Geoffrey S. Mackay and Christine P. Mackay" filed Aug 12, 1994, closed Dec 12, 1995. Geoffrey MacKay (listed on the same filings) is listed as Debtor ("Geoffrey S. Mackay and Christine P. Mackay"). Our match estimate: 70%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, D. Massachusetts ↗Geoffrey MacKay — PartnerFacts page ↗
Sources
Worth asking · May 27, 2009

100% of the money raised went to insiders — Miragen Therapeutics, Inc.

The May 27, 2009 Form D reports $52,983 sold and $52,983 of the proceeds used for payments to officers, directors or promoters.

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D · May 27, 2009 ↗Miragen Therapeutics, Inc. — PartnerFacts page ↗
Sources
Worth asking · Mar 11, 2011 – Sep 14, 2017

Bruce Booth appears on 4 deals that stopped filing before reaching their target

Rodin Therapeutics, Inc. (last filing Sep 14, 2017; $10,826,792 sold of $27,066,981); Atlas Venture Fund X, L.P. (last filing Dec 18, 2014; $0 sold of $250,000,000); On-Q-ity, Inc. (last filing Feb 28, 2012; $2,500,000 sold of $6,533,458); Nimbus Discovery, LLC (last filing Mar 11, 2011; $3,500,000 sold of $15,000,000). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Rodin Therapeutics, Inc. — PartnerFacts page ↗Atlas Venture Fund X, L.P. — PartnerFacts page ↗On-Q-ity, Inc. — PartnerFacts page ↗Nimbus Discovery, LLC — PartnerFacts page ↗
Sources
Note · Sep 18, 2020 – Oct 5, 2020

Form D filed 17 days after the first sale — Vigil Neuroscience, Inc.

The filing says the first sale was Sep 18, 2020. The Form D was filed Oct 5, 2020 — 17 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 2 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Oct 5, 2020 ↗Vigil Neuroscience, Inc. — PartnerFacts page ↗
Sources
Note · Oct 3, 2014 – Oct 20, 2014

Form D filed 17 days after the first sale — Unum Therapeutics Inc.

The filing says the first sale was Oct 3, 2014. The Form D was filed Oct 20, 2014 — 17 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 2 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Oct 20, 2014 ↗Unum Therapeutics Inc. — PartnerFacts page ↗
Sources
Note · Apr 29, 2009 – Oct 17, 2022

18 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Matchpoint Therapeutics Inc. (latest filing Oct 17, 2022) · No amendment in the last 12 months on an offering that may still be open — Lysosomal Therapeutics, Inc. (latest filing Nov 7, 2019) · No amendment in the last 12 months on an offering that may still be open — Tectonic Therapeutic, Inc. (latest filing Feb 2, 2018) · No amendment in the last 12 months on an offering that may still be open — Rodin Therapeutics, Inc. (latest filing Sep 14, 2017) · No amendment in the last 12 months on an offering that may still be open — Magenta Therapeutics, Inc. (latest filing May 5, 2017) · and 13 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Oct 17, 2022 ↗Matchpoint Therapeutics Inc. — PartnerFacts page ↗Form D · Nov 7, 2019 ↗Lysosomal Therapeutics, Inc. — PartnerFacts page ↗
Sources
Worth asking · Aug 6, 2018 – Oct 31, 2019

Bruce Booth is no longer listed on the Oct 31, 2019 amendment — MIRAGEN THERAPEUTICS, INC.

Bruce Booth appears on the Aug 6, 2018 Form D (director) but not on the Oct 31, 2019 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Aug 6, 2018 ↗Form D/A · Oct 31, 2019 ↗Bruce Booth — PartnerFacts page ↗MIRAGEN THERAPEUTICS, INC. — PartnerFacts page ↗
Sources
Note · Nov 12, 2015 – Feb 14, 2017

Bruce Booth's role changed at Miragen Therapeutics, Inc.: executive officer, director → director

The Nov 12, 2015 filing lists Bruce Booth as executive officer, director; the Feb 14, 2017 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Nov 12, 2015 ↗Form D · Feb 14, 2017 ↗Bruce Booth — PartnerFacts page ↗Miragen Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jun 26, 2014 – Feb 17, 2015

Bruce Booth's role changed at Miragen Therapeutics, Inc.: director → executive officer, director

The Jun 26, 2014 filing lists Bruce Booth as director; the Feb 17, 2015 Form D lists executive officer, director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D/A · Jun 26, 2014 ↗Form D · Feb 17, 2015 ↗Bruce Booth — PartnerFacts page ↗Miragen Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Apr 24, 2012 – Jun 26, 2014

Bruce Booth's role changed at Miragen Therapeutics, Inc.: executive officer, director → director

The Apr 24, 2012 filing lists Bruce Booth as executive officer, director; the Jun 26, 2014 Form D/A lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Apr 24, 2012 ↗Form D/A · Jun 26, 2014 ↗Bruce Booth — PartnerFacts page ↗Miragen Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · May 14, 2009 – Jan 2, 2019

4 offerings changed their target amount between filings

Offering amount changed between filings — Atlas Venture Opportunity Fund I, L.P. · Offering amount changed between filings — Lysosomal Therapeutics, Inc. · Offering amount changed between filings — AVILA THERAPEUTICS INC · Offering amount changed between filings — Miragen Therapeutics, Inc.

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · Nov 29, 2018 ↗Form D/A (later) · Jan 2, 2019 ↗Atlas Venture Opportunity Fund I, L.P. — PartnerFacts page ↗Form D (earlier) · Feb 11, 2015 ↗
Sources
Note · Jul 31, 2009 – Jul 6, 2010

Minimum investment changed between filings — AVILA THERAPEUTICS INC

The Jul 31, 2009 filing lists a minimum of $9,531; the Jul 6, 2010 Form D/A lists $0.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Jul 31, 2009 ↗Form D/A (later) · Jul 6, 2010 ↗AVILA THERAPEUTICS INC — PartnerFacts page ↗
Sources
Note · May 14, 2009 – Jul 31, 2009

Minimum investment changed between filings — AVILA THERAPEUTICS INC

The May 14, 2009 filing lists a minimum of $7,206; the Jul 31, 2009 Form D lists $9,531.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · May 14, 2009 ↗Form D (later) · Jul 31, 2009 ↗AVILA THERAPEUTICS INC — PartnerFacts page ↗
Sources
Note · May 27, 2009 – Nov 12, 2015

Bruce Booth is written 2 different ways on the filings

listed as "Bruce Booth" on 42 filings (from May 27, 2009), and "Bruce L Booth" on 5 filings (from Nov 12, 2015).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D/A · May 27, 2009 ↗Form D · Nov 12, 2015 ↗Bruce Booth — PartnerFacts page ↗
Sources
Note · Oct 5, 2020 – Aug 25, 2021

Industry group changed between filings — Vigil Neuroscience, Inc.

"Other" (Oct 5, 2020); then "Biotechnology" (Jun 15, 2021); then "Pharmaceuticals" (Aug 25, 2021 to Aug 29, 2022).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Oct 5, 2020 ↗Form D/A · Jun 15, 2021 ↗Form D · Aug 25, 2021 ↗Vigil Neuroscience, Inc. — PartnerFacts page ↗
Sources
Note · Oct 20, 2014 – Jun 25, 2015

Industry group changed between filings — Unum Therapeutics Inc.

"Other Health Care" (Oct 20, 2014); then "Biotechnology" (Jun 25, 2015).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Oct 20, 2014 ↗Form D · Jun 25, 2015 ↗Unum Therapeutics Inc. — PartnerFacts page ↗
Sources
Note · May 14, 2009 – Jul 6, 2010

Reported revenue range changed between filings — AVILA THERAPEUTICS INC

"No Revenues" (May 14, 2009); then "Decline to Disclose" (Jul 6, 2010).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · May 14, 2009 ↗Form D/A · Jul 6, 2010 ↗AVILA THERAPEUTICS INC — PartnerFacts page ↗
Sources
Note · Jun 4, 2014

Same name, different state: "Bruce Booth" (CA) is a separate record

This page covers filings where the address state is CO or MA. A separate record, "Bruce Booth" with address state CA, is listed on 1 filing — most recently by NUMERATE INC (Jun 4, 2014). Both records have filings in the same period (Jun 4, 2014).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Bruce Booth (CA) — PartnerFacts page ↗Form D · Jun 4, 2014 ↗NUMERATE INC — PartnerFacts page ↗Bruce Booth (CO,MA) — this page ↗
Sources
Note · Apr 29, 2010 – Mar 11, 2011

Address moved from Waltham, MA to Cambridge, MA — Nimbus Discovery, LLC

The people listed on the Apr 29, 2010 filing give Waltham, MA; on the Mar 11, 2011 filing they give Cambridge, MA. The address now on file (25 First Street, Suite 303, Cambridge, MA) is a registered-agent or shared-office address used by 10 issuers.

What this means A registered agent's address is a mailbox, not where the team works. Ask where the business actually operates.

Form D · Apr 29, 2010 ↗Form D · Mar 11, 2011 ↗Nimbus Discovery, LLC — PartnerFacts page ↗
Sources
Note · May 27, 2009 – Sep 4, 2025

Bruce Booth is listed with 2 different address states: CO, MA

CO on 11 filings (May 27, 2009 to Aug 6, 2018); MA on 36 filings (Jul 31, 2009 to Sep 4, 2025).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D/A · May 27, 2009 ↗Form D · Jul 31, 2009 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

2 of 39 offerings report sales commissions totalling $4,574,999; 0 report finder's fees; 1 reports proceeds to related persons totalling $250,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Sep 4, 2025 D
Atlas Venture Opportunity Fund Ill, L.P.
File 021-556589
$0$0$0
An affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Dec 5, 2024 D
Atlas Venture Fund XIV, L.P.
File 021-531177
$0$0$0
An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Oct 17, 2022 D
Matchpoint Therapeutics Inc.
File 021-462017
$0$0$0None listed on this filingEDGAR ↗
Aug 29, 2022 D
Vigil Neuroscience, Inc.
File 021-457309
$3,375,000$0$0Jefferies LLC BrokerCheck CRD 2347 ↗EDGAR ↗
Mar 3, 2022 D
Atlas Venture Fund XIII, L.P.
File 021-435762
$0$0$0
An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Oct 1, 2021 D
Atlas Venture Opportunity Fund II, L.P.
File 021-415392
$0$0$0
An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Aug 25, 2021 D
Vigil Neuroscience, Inc.
File 021-411167
$0$0$0None listed on this filingEDGAR ↗
Jun 15, 2021 D/A
Vigil Neuroscience, Inc.
File 021-377071
$0$0$0None listed on this filingEDGAR ↗
Jun 4, 2020 D
Atlas Venture Fund XII, L.P.
File 021-368325
$0$0$0
An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Nov 7, 2019 D
Lysosomal Therapeutics, Inc.
File 021-352903
$0$0$0None listed on this filingEDGAR ↗
Jan 2, 2019 D/A
Atlas Venture Opportunity Fund I, L.P.
File 021-326809
$0$0$0None listed on this filingEDGAR ↗
Aug 6, 2018 D
MIRAGEN THERAPEUTICS, INC.
File 021-318573
$0$0$0None listed on this filingEDGAR ↗
Apr 9, 2018 D
Magenta Therapeutics, Inc.
File 021-309660
$0$0$0None listed on this filingEDGAR ↗
Feb 2, 2018 D
Tectonic Therapeutic, Inc.
File 021-304752
$0$0$0None listed on this filingEDGAR ↗
Nov 22, 2017 D
MIRAGEN THERAPEUTICS, INC.
File 021-299421
$0$0$0None listed on this filingEDGAR ↗
Sep 14, 2017 D
Rodin Therapeutics, Inc.
File 021-294765
$0$0$0None listed on this filingEDGAR ↗
Jun 30, 2017 D
Atlas Venture Fund XI, L.P.
File 021-289898
$0$0$0
An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
May 5, 2017 D
Magenta Therapeutics, Inc.
File 021-286150
$0$0$0None listed on this filingEDGAR ↗
Feb 14, 2017 D
Miragen Therapeutics, Inc.
File 021-280608
$1,199,999$0$0Wedbush Securities Inc. BrokerCheck CRD 877 ↗
via Wedbush Securities Inc. (CRD 877 ↗)
EDGAR ↗
Jan 18, 2017 D/A
Lysosomal Therapeutics, Inc.
File 021-233905
$0$0$0None listed on this filingEDGAR ↗
Nov 23, 2016 D
Magenta Therapeutics, Inc.
File 021-275074
$0$0$0None listed on this filingEDGAR ↗
Oct 6, 2016 D
Lysosomal Therapeutics, Inc.
File 021-272003
$0$0$250,000 (est.)None listed on this filingEDGAR ↗
Aug 3, 2016 D
Tectonic Therapeutic, Inc.
File 021-268222
$0$0$0None listed on this filingEDGAR ↗
Nov 12, 2015 D
Miragen Therapeutics, Inc.
File 021-251118
$0$0$0None listed on this filingEDGAR ↗
Jun 25, 2015 D
Unum Therapeutics Inc.
File 021-242431
$0$0$0None listed on this filingEDGAR ↗
Feb 17, 2015 D
Miragen Therapeutics, Inc.
File 021-234182
$0$0$0None listed on this filingEDGAR ↗
Dec 18, 2014 D
Atlas Venture Fund X, L.P.
File 021-230375
$0$0$0
An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Oct 20, 2014 D
Unum Therapeutics Inc.
File 021-226748
$0$0$0None listed on this filingEDGAR ↗
Jun 26, 2014 D/A
Miragen Therapeutics, Inc.
File 021-177167
$0$0$0None listed on this filingEDGAR ↗
Dec 5, 2012 D
Larimar Therapeutics, Inc.
File 021-187910
$0$0$0None listed on this filingEDGAR ↗
Aug 28, 2012 D
Larimar Therapeutics, Inc.
File 021-183316
$0$0$0None listed on this filingEDGAR ↗
Feb 28, 2012 D
On-Q-ity, Inc.
File 021-174063
$0$0$0None listed on this filingEDGAR ↗
Jan 3, 2012 D/A
Miragen Therapeutics, Inc.
File 021-148007
$0$0$0None listed on this filingEDGAR ↗
Jul 12, 2011 D
Larimar Therapeutics, Inc.
File 021-162666
$0$0$0 (est.)None listed on this filingEDGAR ↗
Mar 11, 2011 D
Nimbus Discovery, LLC
File 021-156591
$0$0$0None listed on this filingEDGAR ↗
Jul 6, 2010 D/A
AVILA THERAPEUTICS INC
File 021-117636
$0$0$0None listed on this filingEDGAR ↗
Apr 29, 2010 D
Nimbus Discovery, LLC
File 021-141296
$0$0$0None listed on this filingEDGAR ↗
Mar 2, 2010 D/A
Larimar Therapeutics, Inc.
File 021-94401
$0$0$0None listed on this filingEDGAR ↗
May 27, 2009 D/A
Miragen Therapeutics, Inc.
File 021-110805
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 21

Every issuer that named Bruce Booth on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

AV
Pooled Investment Fund · group: Atlas Venture

Atlas Venture Opportunity Fund Ill, L.P.

Cambridge, MA · Sep 4, 2025
  • Sep 4, 2025 · D · $400,000,000 sold of $400,000,000 · 84 investors · min. No minimum reported · role: Executive Officer (Member of the sole member of the GPLLC) EDGAR ↗

Raised $400M from 84 investors (100% of the $400M target) as of the latest filing. Bruce is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Atlas Venture

Atlas Venture Fund XIV, L.P.

Cambridge, MA · Dec 5, 2024
  • Dec 5, 2024 · D · $450,000,000 sold of $450,000,000 · 84 investors · min. No minimum reported · role: Executive Officer (Member of the sole member of the GPLLC) EDGAR ↗

Raised $450M from 84 investors (100% of the $450M target) as of the latest filing. Bruce is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Pharmaceuticals

Matchpoint Therapeutics Inc.

Cambridge, MA · Oct 17, 2022
  • Oct 17, 2022 · D · $41,999,994 sold of $69,999,990 · 15 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $42M from 15 investors (60% of the $70M target) as of the latest filing. Bruce is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VN
Pharmaceuticals

Vigil Neuroscience, Inc.

Cambridge, MA · Oct 5, 2020 → Aug 29, 2022 · 4 filings
  • Aug 29, 2022 · D · $74,999,705 sold of $74,999,705 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 25, 2021 · D · $89,999,961 sold of $89,999,961 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 15, 2021 · D/A · $49,999,989 sold of $49,999,989 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 5, 2020 · D · $29,999,995 sold of $49,999,989 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $90M from 19 investors (100% of the $75M target) as of the latest filing. Bruce is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Atlas Venture

Atlas Venture Fund XIII, L.P.

Cambridge, MA · Mar 3, 2022
  • Mar 3, 2022 · D · $450,000,000 sold of $450,000,000 · 87 investors · min. No minimum reported · role: Executive Officer (Member of the sole member of the GPLLC) EDGAR ↗

Raised $450M from 87 investors (100% of the $450M target) as of the latest filing. Bruce is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Atlas Venture

Atlas Venture Opportunity Fund II, L.P.

Cambridge, MA · Oct 1, 2021
  • Oct 1, 2021 · D · $300,000,000 sold of $300,000,000 · 69 investors · min. No minimum reported · role: Executive Officer (Member of the sole member of the GPLLC) EDGAR ↗

Raised $300M from 69 investors (100% of the $300M target) as of the latest filing. Bruce is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Atlas Venture

Atlas Venture Fund XII, L.P.

Cambridge, MA · Jun 4, 2020
  • Jun 4, 2020 · D · $400,000,000 sold of $400,000,000 · 85 investors · min. No minimum reported · role: Executive Officer (Member of the sole member of the GPLLC) EDGAR ↗

Raised $400M from 85 investors (100% of the $400M target) as of the latest filing. Bruce is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LT
Biotechnology

Lysosomal Therapeutics, Inc.

Cambridge, MA · Feb 11, 2015 → Nov 7, 2019 · 4 filings
  • Nov 7, 2019 · D · $1,000,000 sold of $3,000,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 18, 2017 · D/A · $26,124,936 sold of $26,124,936 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 6, 2016 · D · $6,000,000 sold of $6,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 11, 2015 · D · $10,000,002 sold of $20,000,004 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $26.1M from 11 investors (100% of the $3M target) as of the latest filing. Bruce is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Atlas Venture

Atlas Venture Opportunity Fund I, L.P.

Cambridge, MA · Nov 29, 2018 → Jan 2, 2019 · 2 filings
  • Jan 2, 2019 · D/A · $250,000,000 sold of $250,000,000 · 47 investors · min. No minimum reported · role: Executive Officer (Member of the sole member of the GPLLC) EDGAR ↗
  • Nov 29, 2018 · D · $0 sold of $200,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of the sole member of the GPLLC) EDGAR ↗

Raised $250M from 47 investors (100% of the $250M target) as of the latest filing. Bruce is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Biotechnology · group: Miragen Therapeutics

MIRAGEN THERAPEUTICS, INC.

Boulder, CO · Nov 22, 2017 → Aug 6, 2018 · 2 filings
  • Aug 6, 2018 · D · $1,000,000 sold of $5,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 22, 2017 · D · $172,294 sold of $172,294 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $91M from 22 investors (100% of the $5M target) as of the latest filing. Bruce is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Biotechnology

Magenta Therapeutics, Inc.

Cambridge, MA · Nov 23, 2016 → Apr 9, 2018 · 3 filings
  • Apr 9, 2018 · D · $52,299,655 sold of $52,299,655 · 23 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 5, 2017 · D · $46,000,000 sold of $50,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 23, 2016 · D · $17,718,974 sold of $48,663,974 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $52.3M from 23 investors (100% of the $52.3M target) as of the latest filing. Bruce is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TT
Biotechnology · group: Tectonic Therapeutic

Tectonic Therapeutic, Inc.

Watertown, MA · Aug 3, 2016 → Feb 2, 2018 · 2 filings
  • Feb 2, 2018 · D · $60,499,978 sold of $60,999,978 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 3, 2016 · D · $7,500,000 sold of $25,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $185M from 29 investors (100% of the $61M target) as of the latest filing. Bruce is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RT
Other Health Care

Rodin Therapeutics, Inc.

Cambridge, MA · Sep 14, 2017
  • Sep 14, 2017 · D · $10,826,792 sold of $27,066,981 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10.8M from 6 investors (40% of the $27.1M target) as of the latest filing. Bruce is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Atlas Venture

Atlas Venture Fund XI, L.P.

Cambridge, MA · Jun 30, 2017
  • Jun 30, 2017 · D · $350,000,000 sold of $350,000,000 · 70 investors · min. No minimum reported · role: Executive Officer (Member of the sole member of the GPLLC) EDGAR ↗

Raised $350M from 70 investors (100% of the $350M target) as of the latest filing. Bruce is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Biotechnology · group: Miragen Therapeutics

Miragen Therapeutics, Inc.

Boulder, CO · May 27, 2009 → Feb 14, 2017 · 9 filings
  • Feb 14, 2017 · D · $40,703,067 sold of $40,703,067 · 25 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 12, 2015 · D · $24,968,495 sold of $41,059,739 · 34 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Feb 17, 2015 · D · $8,499,962 sold of $20,000,000 · 29 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jun 26, 2014 · D/A · $12,999,906 sold of $19,999,866 · 29 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 24, 2012 · D · $5,999,946 sold of $19,999,866 · 29 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 3, 2012 · D/A · $6,000,000 sold of $6,000,000 · 24 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Sep 21, 2010 · D · $3,000,000 sold of $6,000,000 · 24 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • May 27, 2009 · D/A · $11,999,997 sold of $11,999,997 · 28 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • May 27, 2009 · D · $52,983 sold of $52,983 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $40.7M from 34 investors (100% of the $40.7M target) as of the latest filing. Bruce is listed as director, executive officer on 9 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

UT
Biotechnology

Unum Therapeutics Inc.

Cambridge, MA · Oct 20, 2014 → Jun 25, 2015 · 2 filings
  • Jun 25, 2015 · D · $65,000,000 sold of $65,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 20, 2014 · D · $6,252,685 sold of $12,252,685 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $104.4M from 22 investors (100% of the $65M target) as of the latest filing. Bruce is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Atlas Venture

Atlas Venture Fund X, L.P.

Cambridge, MA · Dec 18, 2014
  • Dec 18, 2014 · D · $0 sold of $250,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of the General Partner and the GPLLC) EDGAR ↗

No sales reported yet as of the latest filing. Bruce is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LT
Other Health Care

Larimar Therapeutics, Inc.

Bala Cynwyd, PA · Mar 1, 2010 → Dec 5, 2012 · 5 filings
  • Dec 5, 2012 · D · $21,761,570 sold of Indefinite · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 28, 2012 · D · $3,000,000 sold of Indefinite · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 12, 2011 · D · $6,085,933 sold of Indefinite · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 2, 2010 · D/A · $8,100,000 sold of $10,125,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 1, 2010 · D · $8,100,000 sold of $10,125,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $82.1M from 24 investors as of the latest filing. Bruce is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

OQ
Biotechnology

On-Q-ity, Inc.

Waltham, MA · Feb 28, 2012
  • Feb 28, 2012 · D · $2,500,000 sold of $6,533,458 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $2.5M from 4 investors (38% of the $6.53M target) as of the latest filing. Bruce is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

ND
Pharmaceuticals

Nimbus Discovery, LLC

Cambridge, MA · Apr 29, 2010 → Mar 11, 2011 · 2 filings
  • Mar 11, 2011 · D · $1,500,000 sold of $15,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 29, 2010 · D · $3,500,000 sold of $3,500,000 · 2 investors · min. No minimum reported · role: Director (Chairman and Manager) EDGAR ↗

Raised $3.5M from 3 investors (23% of the $15M target) as of the latest filing. Bruce is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AT
Biotechnology

AVILA THERAPEUTICS INC

Waltham, MA · Jul 31, 2009 → Jul 6, 2010 · 2 filings
  • Jul 6, 2010 · D/A · $22,500,000 sold of $30,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 31, 2009 · D · $17,500,000 sold of $30,000,000 · 9 investors · min. $9,531 · role: Director EDGAR ↗

Raised $22.5M from 9 investors (75% of the $30M target) as of the latest filing. Bruce is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Bruce Booth — CA, 1 issuer, Jun 4, 2014 → Jun 4, 2014 · no shared issuer

People around Bruce 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

AV
Management entity

Atlas Venture Associates X, L.P.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Bruce Booth. Their page shows their other deals.

AV
Management entity

Atlas Venture Associates XI, L.P.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Bruce Booth. Their page shows their other deals.

TH
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas Hughes

Executive Officer, Director · 14 shared filings (3 issuers) · also on 1 other issuer

Listed on the same filings as Bruce Booth. Their page shows their other deals.

WM
No photo found yet (own website and image search run after this page is viewed)
Person

William Marshall

Executive Officer, Director · 11 shared filings (2 issuers) · also on 3 other issuers

William Marshall is on 5 issuers in total — a repeat sponsor. Their page lists every one.

KL
No photo found yet (own website and image search run after this page is viewed)
Person

Kyle Lefkoff

Director · 9 shared filings (1 issuer) · also on 15 other issuers

Kyle Lefkoff is on 16 issuers in total — a repeat sponsor. Their page lists every one.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

Jason Rhodes

Executive Officer · 9 shared filings (8 issuers) · also on 3 other issuers

Jason Rhodes is on 11 issuers in total — a repeat sponsor. Their page lists every one.

DG
No photo found yet (own website and image search run after this page is viewed)
Person

David Grayzel

Executive Officer · 8 shared filings (7 issuers) · also on 8 other issuers

David Grayzel is on 15 issuers in total — a repeat sponsor. Their page lists every one.

MC
No photo found yet (own website and image search run after this page is viewed)
Person

Marvin Caruthers

Director · 8 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Bruce Booth. Their page shows their other deals.

KB
No photo found yet (own website and image search run after this page is viewed)
Person

Kevin Bitterman

Executive Officer · 8 shared filings (7 issuers) · also on 17 other issuers

Kevin Bitterman is on 24 issuers in total — a repeat sponsor. Their page lists every one.

JL
No photo found yet (own website and image search run after this page is viewed)
Person

Jason Leverone

Executive Officer · 8 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Bruce Booth. Their page shows their other deals.

JF
No photo found yet (own website and image search run after this page is viewed)
Person

Jean-Francois Formela

Executive Officer · 7 shared filings (6 issuers) · also on 20 other issuers

Jean-Francois Formela is on 26 issuers in total — a repeat sponsor. Their page lists every one.

PB
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Barrett

Director, Executive Officer · 6 shared filings (2 issuers) · also on 10 other issuers

Peter Barrett is on 12 issuers in total — a repeat sponsor. Their page lists every one.

CT
No photo found yet (own website and image search run after this page is viewed)
Person

Clay Thorp

Director · 6 shared filings (2 issuers) · also on 17 other issuers

Clay Thorp is on 19 issuers in total — a repeat sponsor. Their page lists every one.

MB
No photo found yet (own website and image search run after this page is viewed)
Person

Mitchell S. Bloom

Executive Officer · 5 shared filings (1 issuer) · also on 11 other issuers

Mitchell S. Bloom is on 12 issuers in total — a repeat sponsor. Their page lists every one.

KS
No photo found yet (own website and image search run after this page is viewed)
Person

Kevin Starr

Director · 5 shared filings (1 issuer) · also on 8 other issuers

Kevin Starr is on 9 issuers in total — a repeat sponsor. Their page lists every one.

MJ
No photo found yet (own website and image search run after this page is viewed)
Person

Matthias Jaffe

Executive Officer · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Bruce Booth. Their page shows their other deals.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

John Creecy

Director · 5 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Bruce Booth. Their page shows their other deals.

MG
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Gladstone

Executive Officer · 5 shared filings (5 issuers) · also on 2 other issuers

Michael Gladstone is on 7 issuers in total — a repeat sponsor. Their page lists every one.

VS
No photo found yet (own website and image search run after this page is viewed)
Person

Vicki Sato

Director · 4 shared filings (2 issuers) · also on 4 other issuers

Vicki Sato is on 6 issuers in total — a repeat sponsor. Their page lists every one.

AG
No photo found yet (own website and image search run after this page is viewed)
Person

Avi Goldberg

Director · 4 shared filings (1 issuer)

Listed on the same filings as Bruce Booth. Their page shows their other deals.

RC
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Carpenter

Director, Executive Officer · 4 shared filings (1 issuer) · also on 5 other issuers

Robert Carpenter is on 6 issuers in total — a repeat sponsor. Their page lists every one.

SH
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Hall

Director · 4 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Bruce Booth. Their page shows their other deals.

CB
No photo found yet (own website and image search run after this page is viewed)
Person

Cornelis Been

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as Bruce Booth. Their page shows their other deals.

IL
No photo found yet (own website and image search run after this page is viewed)
Person

Ivana Magovcevic-Liebisch

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as Bruce Booth. Their page shows their other deals.

GK
No photo found yet (own website and image search run after this page is viewed)
Person

Gerhard Koenig

Director · 4 shared filings (1 issuer)

Listed on the same filings as Bruce Booth. Their page shows their other deals.

LT
No photo found yet (own website and image search run after this page is viewed)
Person

Louis Tartaglia

Director · 3 shared filings (1 issuer) · also on 4 other issuers

Louis Tartaglia is on 5 issuers in total — a repeat sponsor. Their page lists every one.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

Joshua Resnick

Director · 3 shared filings (2 issuers) · also on 11 other issuers

Joshua Resnick is on 13 issuers in total — a repeat sponsor. Their page lists every one.

AB
No photo found yet (own website and image search run after this page is viewed)
Person

Alexis Borisy

Director · 3 shared filings (1 issuer) · also on 15 other issuers

Alexis Borisy is on 16 issuers in total — a repeat sponsor. Their page lists every one.

DR
No photo found yet (own website and image search run after this page is viewed)
Person

David Rodman

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Bruce Booth. Their page shows their other deals.

CM
No photo found yet (own website and image search run after this page is viewed)
Person

Christopher J Morl

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Bruce Booth. Their page shows their other deals.

BD
No photo found yet (own website and image search run after this page is viewed)
Person

BERNARD DAVITIAN

Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Bruce Booth. Their page shows their other deals.

DG
No photo found yet (own website and image search run after this page is viewed)
Person

Daniel Geffken

Executive Officer · 3 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Bruce Booth. Their page shows their other deals.

DS
No photo found yet (own website and image search run after this page is viewed)
Person

David Scadden

Director · 3 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Bruce Booth. Their page shows their other deals.

MB
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Bonney

Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Bruce Booth. Their page shows their other deals.

The team behind the deals

AV
Sponsor group

Atlas Venture

11 issuers · 15 filings · $2.66B reported sold · 2011–2026

One team, 11 deal companies. Bruce Booth is listed on 8 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Bruce Booth.

MT
Sponsor group

Miragen Therapeutics

2 issuers · 13 filings · $131.7M reported sold · 2009–2020

One team, 2 deal companies. Bruce Booth is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Bruce Booth.

TT
Sponsor group

Tectonic Therapeutic

2 issuers · 4 filings · $265.1M reported sold · 2016–2025

One team, 2 deal companies. Bruce Booth is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Bruce Booth.

Same business address

32 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

None of the 21 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Bruce Booth by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 21 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Bruce Booth is listed on: none on file. No website or social profile named in Atlas Venture Fund XIV, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #84,101 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Cambridge, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Colorado state courts — find the court ↗Massachusetts MassCourts ↗Pennsylvania UJS portal case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Colorado Secretary of State business search ↗Massachusetts Secretary of State business search ↗Pennsylvania Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Bruce Booth appears on a new Form D, or when a court case or SEC action is matched to them. See plans →